The Benefit of Adjuvant Chemotherapy in Pathological T1-3N0M0 Rectal Mucinous Adenocarcinoma: No Improvement Survival Outcomes Based on Long-term Survival Analysis of Large Population Data

Overview

Journal J Gastrointest Oncol

Date 2024 Sep 16

PMID 39279951

Authors

Hualin Liao

Tengyu Zeng

Xianqiang Xie

Jiyang Li

Dongsheng Li

Kejin Yan

Fan Chen

Hongliang Zhu

Affiliations

Soon will be listed here.

Abstract

Background: Currently, the benefits of the administration of adjuvant chemotherapy (AT) in pathological low-risk rectal mucinous adenocarcinoma (RM) with T1-3N0M0 are unclear. The objective of this study is to retrospectively investigate the clinical significance of AT in terms of survival outcomes for patients with pathological T1-3N0M0 RM using data from a large population.

Methods: The patient data were collected from the Surveillance, Epidemiology, and End Results (SEER) Program. The Chi-squared test was used to analyze categorical variables. The survival curves were compared using the log-rank test and the Kaplan-Meier method. A multivariate proportional hazards regression (Cox) model was applied to identify the independent prognostic factors of survival outcomes. Propensity score matching (PSM) was utilized to eliminate the differences between groups and estimate AT's effect.

Results: The median follow-up duration for the rectal cancer (RC) cohort was 116 months. Multivariate analyses revealed that RM was a significant adverse prognostic factor, correlating with poorer overall survival (OS) and cancer-specific survival (CSS) for RC [hazard ratio (HR): 1.226, 95% confidence interval (CI): 1.094-1.375, P<0.001; HR: 1.446, 95% CI: 1.242-1.683, P<0.001]. Among patients with RM, the rates of 5-year OS and CSS were 68.6% and 79.3% in the AT (-) group, respectively. Additionally, the AT (+) group exhibited similar rates of 65.6% for 5-year OS and 74% for CSS (P=0.80, P=0.26). Subtype analysis according to preoperative therapy status showed that AT also did not significantly affect survival outcomes (P=0.65, P=0.34; P=0.90, P=0.76).

Conclusions: Our study found that RM is a poor prognostic factor in pathological T1-3N0M0 RC. However, AT does not appear necessary to improve survival outcomes of pathological T1-3N0M0 RM.

References

Cercek A, Roxburgh C, Strombom P, Smith J, Temple L, Nash G . Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncol. 2018; 4(6):e180071. PMC: 5885165. DOI: 10.1001/jamaoncol.2018.0071. View

Sugarbaker P . Mucinous colorectal carcinoma. J Surg Oncol. 2001; 77(4):282-3. DOI: 10.1002/jso.1111. View

Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T . Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2019; 25(1):1-42. PMC: 6946738. DOI: 10.1007/s10147-019-01485-z. View

Mekenkamp L, Heesterbeek K, Koopman M, Tol J, Teerenstra S, Venderbosch S . Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur J Cancer. 2012; 48(4):501-9. DOI: 10.1016/j.ejca.2011.12.004. View

Bregni G, Akin Telli T, Camera S, Deleporte A, Moretti L, Bali A . Adjuvant chemotherapy for rectal cancer: Current evidence and recommendations for clinical practice. Cancer Treat Rev. 2020; 83:101948. DOI: 10.1016/j.ctrv.2019.101948. View

Morikawa T, Kuchiba A, Qian Z, Mino-Kenudson M, Hornick J, Yamauchi M . Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. Ann Surg Oncol. 2011; 19(6):1944-53. PMC: 3321113. DOI: 10.1245/s10434-011-2174-5. View

Liu S, Jiang T, Xiao L, Yang S, Liu Q, Gao Y . Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis. Oncologist. 2021; 26(9):e1555-e1566. PMC: 8417863. DOI: 10.1002/onco.13824. View

Tarantino I, Huttner F, Warschkow R, Schmied B, Diener M, Ulrich A . Prognostic Relevance of Mucinous Subtype in a Population-based Propensity Score Analysis of 40,083 Rectal Cancer Patients. Ann Surg Oncol. 2015; 23(5):1576-86. DOI: 10.1245/s10434-015-5029-7. View

Quere P, Facy O, Manfredi S, Jooste V, Faivre J, Lepage C . Epidemiology, Management, and Survival of Peritoneal Carcinomatosis from Colorectal Cancer: A Population-Based Study. Dis Colon Rectum. 2015; 58(8):743-52. DOI: 10.1097/DCR.0000000000000412. View

10.

Kidner T, Ozao-Choy J, Yoon J, Bilchik A . Should quality measures for lymph node dissection in colon cancer be extrapolated to rectal cancer?. Am J Surg. 2012; 204(6):843-7. DOI: 10.1016/j.amjsurg.2012.05.003. View

11.

Liao H, Li T, Liang Y, Liu Y, Yuan Y, Li M . The benefits of adjuvant chemotherapy are associated with the kind of neoadjuvant therapy in stage ypI rectal cancer: evidence based on population analysis. Int J Colorectal Dis. 2023; 38(1):235. DOI: 10.1007/s00384-023-04530-6. View

12.

Liao H, Tang C, Zhou Z, Shi H, Li T, Liang Y . Adjuvant Radiotherapy Is Not Necessary for Stage III Mucinous Rectal Cancer: Evidence Based on Long Survival Analysis from SEER Data. J Gastrointest Surg. 2023; 27(12):2857-2866. DOI: 10.1007/s11605-023-05765-y. View

13.

Benson A, Venook A, Al-Hawary M, Cederquist L, Chen Y, Ciombor K . Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018; 16(7):874-901. PMC: 10203817. DOI: 10.6004/jnccn.2018.0061. View

14.

Bhatia R, Gautam S, Cannon A, Thompson C, Hall B, Aithal A . Cancer-associated mucins: role in immune modulation and metastasis. Cancer Metastasis Rev. 2019; 38(1-2):223-236. PMC: 6614013. DOI: 10.1007/s10555-018-09775-0. View

15.

Reynolds I, OConnell E, Fichtner M, Blumel A, Mason S, Kinross J . An Insight Into the Driver Mutations and Molecular Mechanisms Underlying Mucinous Adenocarcinoma of the Rectum. Dis Colon Rectum. 2021; 64(6):677-688. DOI: 10.1097/DCR.0000000000001825. View

16.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

17.

Hyngstrom J, Hu C, Xing Y, You Y, Feig B, Skibber J . Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol. 2012; 19(9):2814-21. PMC: 3688065. DOI: 10.1245/s10434-012-2321-7. View

18.

Glasgow S, Yu J, Carvalho L, Shannon W, Fleshman J, McLeod H . Unfavourable expression of pharmacologic markers in mucinous colorectal cancer. Br J Cancer. 2005; 92(2):259-64. PMC: 2361854. DOI: 10.1038/sj.bjc.6602330. View

19.

Carvalho C, Glynne-Jones R . Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer. Lancet Oncol. 2017; 18(6):e354-e363. DOI: 10.1016/S1470-2045(17)30346-7. View

20.

Zhang J, Xie X, Wu Z, Hu H, Cai Y, Li J . Mucinous Adenocarcinoma Predicts Poor Response and Prognosis in Patients With Locally Advanced Rectal Cancer: A Pooled Analysis of Individual Participant Data From 3 Prospective Studies. Clin Colorectal Cancer. 2021; 20(4):e240-e248. DOI: 10.1016/j.clcc.2021.06.004. View